Jasper Therapeutics, Inc. (JSPR)Healthcare | Biotechnology | Redwood City, United States | NasdaqCM
0.70 USD
+0.00
(0.072%)
⇧
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.71 +0.01 (2.044%) ⇧ (Aug. 28, 2026, 7:36 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:34 a.m. EDT
The investment case here is fractured by a severe disconnect between the company's reality and the market's pricing. Fundamentally, this is a distressed biotech play with a catastrophic five-year trajectory; the stock has lost 97% of its value over the last half-decade, and the most recent annual performance was another sharp decline. The balance sheet is fragile, with negative free cash flow and no dividend history to speak of. While the recent news of a merger with Kira Pharmaceuticals provides a potential catalyst, the market has already priced in a significant portion of this optimism, evidenced by the massive discount to the analyst mean target. The options market confirms this tension: speculators are buying deep out-of-the-money calls hoping for a miracle, while existing holders are aggressively buying puts to protect against further erosion. Until the merger closes and delivers tangible value that justifies the current valuation, the risk-reward profile remains skewed heavily toward the downside. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.307196 |
| AutoARIMA | 0.307198 |
| MSTL | 0.332567 |
| AutoTheta | 0.649771 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 25% |
| H-stat | 25.08 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.317 |
| Excess Kurtosis | -0.97 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 19.108 |
| Market Cap | 23,282,210 |
| Forward P/E | -0.27 |
| Beta | 3.03 |
| Website | https://jaspertx.com |
As of Aug. 22, 2026, 1:34 a.m. EDT: Call buyers are overwhelmingly positioned out-of-the-money at strikes significantly above the current price, indicating a speculative bet on a massive rally or binary event like a merger completion. Conversely, put volume is concentrated in-the-money and at lower strikes, suggesting active hedging against downside risk. The stark absence of call volume at near-the-money strikes compared to deep OTM calls highlights a lack of consensus for a modest move, while the heavy put open interest at lower levels acts as a significant floor for downside protection.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.74673915 |
| Address1 | 2,200 Bridge Pkwy |
| Address2 | Suite 102 |
| All Time High | 188.8 |
| All Time Low | 0.315 |
| Ask | 0.8593 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 2.3 - Buy |
| Average Daily Volume10 Day | 790,270 |
| Average Daily Volume3 Month | 1,548,551 |
| Average Volume | 1,548,551 |
| Average Volume10Days | 790,270 |
| Beta | 3.029 |
| Bid | 0.49 |
| Bid Size | 2 |
| Board Risk | 10 |
| Book Value | 0.05 |
| City | Redwood City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.6997 |
| Current Ratio | 1.475 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.7095 |
| Day Low | 0.6601 |
| Debt To Equity | 19.108 |
| Display Name | Jasper Therapeutics |
| Earnings Timestamp | 1,786,734,000 |
| Earnings Timestamp End | 1,794,337,200 |
| Earnings Timestamp Start | 1,794,337,200 |
| Ebitda | -52,303,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.31 |
| Enterprise Value | 16,238,210 |
| Eps Current Year | -2.41 |
| Eps Forward | -2.56 |
| Eps Trailing Twelve Months | -0.93 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.64412 |
| Fifty Day Average Change | 0.05558002 |
| Fifty Day Average Change Percent | 0.0862883 |
| Fifty Two Week Change Percent | -74.67391 |
| Fifty Two Week High | 2.87 |
| Fifty Two Week High Change | -2.1703 |
| Fifty Two Week High Change Percent | -0.7562021 |
| Fifty Two Week Low | 0.315 |
| Fifty Two Week Low Change | 0.3847 |
| Fifty Two Week Low Change Percent | 1.2212698 |
| Fifty Two Week Range | 0.315 - 2.87 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,578,666,600,000 |
| Float Shares | 30,013,987 |
| Forward Eps | -2.56 |
| Forward P E | -0.27332032 |
| Free Cashflow | -39,979,000 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 22 |
| Fullday Change | 0.000500023 |
| Fullday Change Percent | 0.0715136 |
| Fullday Price | 0.714 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.02559 |
| Held Percent Institutions | 0.39501998 |
| Implied Shares Outstanding | 33,274,561 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,704,326,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast stem cell driven diseases in the United States. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factors from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma. Jasper Therapeutics, Inc. was founded in 2018 and is headquartered in Redwood City, California. |
| Long Name | Jasper Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 23,282,210 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_647336542 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -31,771,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 23,292,192 |
| Number Of Analyst Opinions | 4 |
| Open | 0.7095 |
| Operating Cashflow | -60,333,000 |
| Operating Margins | 0.0 |
| Overall Risk | 9 |
| Payout Ratio | 0.0 |
| Phone | 650 549 1400 |
| Post Market Change | 0.014299989 |
| Post Market Change Percent | 2.0437315 |
| Post Market Price | 0.714 |
| Post Market Time | 1,787,960,186 |
| Previous Close | 0.6992 |
| Price Eps Current Year | -0.29033193 |
| Price Hint | 4 |
| Price To Book | 13.9939995 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.932 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.33333 |
| Region | US |
| Regular Market Change | 0.000500023 |
| Regular Market Change Percent | 0.0715136 |
| Regular Market Day High | 0.7095 |
| Regular Market Day Low | 0.6601 |
| Regular Market Day Range | 0.6601 - 0.7095 |
| Regular Market Open | 0.7095 |
| Regular Market Previous Close | 0.6992 |
| Regular Market Price | 0.6997 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 265,031 |
| Return On Assets | -1.1340699 |
| Return On Equity | -2.55045 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 33,274,561 |
| Shares Percent Shares Out | 0.161 |
| Shares Short | 5,358,334 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,661,803 |
| Short Name | Jasper Therapeutics, Inc. |
| Short Percent Of Float | 0.16409999 |
| Short Ratio | 1.93 |
| Source Interval | 15 |
| State | CA |
| Symbol | JSPR |
| Target High Price | 20.0 |
| Target Low Price | 1.5 |
| Target Mean Price | 7.375 |
| Target Median Price | 4.0 |
| Total Cash | 7,314,000 |
| Total Cash Per Share | 0.22 |
| Total Debt | 270,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.93 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.113825 |
| Two Hundred Day Average Change | -0.41412497 |
| Two Hundred Day Average Change Percent | -0.37180436 |
| Type Disp | Equity |
| Volume | 265,031 |
| Website | https://jaspertx.com |
| Zip | 94,065 |